Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current developments in malaria transmission-blocking vaccines.

A Stowers1, R Carter

  • 1Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, NIAID/NIH, 5640 Fishers Lane, Rockville, MD 20852, USA.

Expert Opinion on Biological Therapy
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Training for Rural Practice: What's Needed?

Canadian family physician Medecin de famille canadien·2011
Same author

Strain-specific immunity induced by immunization with pre-erythrocytic stages of Plasmodium chabaudi.

Parasite immunology·2010
Same author

Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study.

British journal of cancer·2010
Same author

On the Value of Test Meals as a Guide to Infant Feeding.

British medical journal·2010
Same author

Pre-oxygenation in healthy volunteers: a comparison of the supine and 45° seated positions*.

Anaesthesia·2010
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Malaria transmission-blocking vaccines (TBVs) target parasite stages in mosquitoes to prevent malaria spread. These vaccines offer a promising new tool to reduce malaria incidence and mortality globally.

Area of Science:

  • Medical Entomology
  • Parasitology
  • Vaccinology

Background:

  • Malaria remains a significant global health threat, causing millions of cases and tens of thousands of deaths annually.
  • Drug-resistant parasites and insecticide-resistant mosquitoes present major challenges to malaria control efforts.
  • Existing control methods are insufficient, necessitating the development of novel strategies like vaccines.

Purpose of the Study:

  • To explore the development and potential of malaria transmission-blocking vaccines (TBVs) as a novel malaria control strategy.
  • To highlight the mechanism of action of TBVs in preventing malaria parasite development within mosquitoes.
  • To assess the potential impact of TBVs on malaria incidence and mortality across various transmission settings.

Main Methods:

Related Experiment Videos

  • TBVs are designed to induce antibodies against parasite antigens expressed during sexual and mosquito mid-gut stages.
  • Vaccination elicits antibodies that are ingested by mosquitoes with infected blood meals.
  • These antibodies inhibit parasite development within the mosquito, thereby blocking transmission.

    • Main Results:

    • Promising recombinant TBV candidate antigens for Plasmodium falciparum and Plasmodium vivax have been developed.
    • Laboratory testing and early clinical trials have shown the potential of these TBV candidates.
    • TBVs have the potential to interrupt malaria transmission in low-transmission areas and reduce disease burden globally.

    Conclusions:

    • Malaria transmission-blocking vaccines (TBVs) represent a promising new approach to malaria control.
    • TBVs can significantly reduce malaria incidence, morbidity, and mortality, particularly in regions with lower transmission rates.
    • Further development and clinical evaluation of TBVs are crucial for their global implementation in malaria eradication efforts.